• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Lee Michael Stewart was granted 828 shares (SEC Form 4)

    4/2/25 9:01:06 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IGMS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Lee Michael Stewart

    (Last) (First) (Middle)
    C/O REDMILE GROUP, LLC
    ONE LETTERMAN DR., BLDG. D, SUITE D3-300

    (Street)
    SAN FRANCISCO CA 94129

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    IGM Biosciences, Inc. [ IGMS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/31/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/31/2025 A 828(1) A $0.00 11,884 D(2)(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. These securities are fully vested restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy.
    2. The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    3. The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    Remarks:
    Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.
    /s/ Michael Lee 04/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IGMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IGMS

    DatePrice TargetRatingAnalyst
    1/10/2025$21.00 → $2.00Outperform → Market Perform
    BMO Capital Markets
    1/10/2025$12.00 → $2.00Equal-Weight → Underweight
    Morgan Stanley
    1/10/2025$27.00 → $2.50Buy → Hold
    Stifel
    1/10/2025$20.00 → $1.50Outperform → Sector Perform
    RBC Capital Mkts
    1/10/2025Buy → Neutral
    Guggenheim
    12/6/2024$21.00Outperform
    BMO Capital Markets
    10/1/2024$12.00 → $9.00Neutral → Underweight
    JP Morgan
    10/1/2024$24.00 → $12.00Buy → Hold
    Truist
    More analyst ratings

    $IGMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • IGM Biosciences downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded IGM Biosciences from Outperform to Market Perform and set a new price target of $2.00 from $21.00 previously

      1/10/25 8:15:47 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded IGM Biosciences from Equal-Weight to Underweight and set a new price target of $2.00 from $12.00 previously

      1/10/25 8:15:47 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences downgraded by Stifel with a new price target

      Stifel downgraded IGM Biosciences from Buy to Hold and set a new price target of $2.50 from $27.00 previously

      1/10/25 8:15:16 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

      – Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory diseases, today announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases.    "Interim data

      1/9/25 1:00:00 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

      – Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended September 30, 2024 and provided an update on recent developments. "The third quarter was transformative for IGM, punct

      11/8/24 7:00:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences to Present at Three Upcoming Investor Conferences

      MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences: Guggenheim Healthcare Innovation Conference on Monday, November 11 at 11:30 a.m. EST in BostonStifel Healthcare Conference on Tuesday, November 19 at 12:40 p.m. EST in New YorkJefferies London Healthcare Conference on Thursday, November 21 at 8:00 a.m. GMT/ 3:00 a.m. EST in London A live webcast of the events will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at http

      11/4/24 7:00:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    SEC Filings

    See more
    • IGM Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - IGM Biosciences, Inc. (0001496323) (Filer)

      6/11/25 5:07:57 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - IGM Biosciences, Inc. (0001496323) (Filer)

      5/29/25 4:05:25 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by IGM Biosciences Inc.

      10-Q - IGM Biosciences, Inc. (0001496323) (Filer)

      5/13/25 4:05:32 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Baker Bros. Advisors Lp bought $3,425,569 worth of shares (395,317 units at $8.67) (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      3/28/24 7:04:05 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baker Bros. Advisors Lp bought $3,431,464 worth of shares (532,693 units at $6.44) (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      12/15/23 5:32:35 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRINCIPAL ACCOUNTING OFFICER Weber Steven sold $2,090 worth of shares (1,865 units at $1.12), decreasing direct ownership by 6% to 27,016 units (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      5/16/25 4:05:57 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lee Michael Stewart was granted 828 shares (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      4/2/25 9:01:06 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Redmile Group, Llc was granted 828 shares (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      4/2/25 9:00:16 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Financials

    Live finance-specific insights

    See more
    • IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

      – Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended September 30, 2024 and provided an update on recent developments. "The third quarter was transformative for IGM, punct

      11/8/24 7:00:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

      – Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler, M.D., appointed as Chief Executive Officer and to Board of Directors – – Cash runway extended into 2027 – – Company to hold conference call and webcast today at 4:30 p.m. EDT – MOUNTAIN VIEW, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in the development

      9/30/24 4:01:00 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

      – Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose cohort cleared in imvotamab rheumatoid arthritis clinical trial – – First dose cohort cleared in imvotamab systemic lupus erythematosus clinical trial – MOUNTAIN VIEW, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) --  IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended June 30, 2024 and provided an update on recent developments. "We continue to make significant progress in the clinical

      8/14/24 7:00:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Medivir Appoints Jens Lindberg as Chief Executive Officer

      STOCKHOLM, Oct. 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has appointed Jens Lindberg as CEO of the company. Jens Lindberg has extensive experience from the pharmaceutical industry and the field of Oncology. He joins from Sedana Medical where he has been VP Commercial and acting CEO. Jens Lindberg started his career in the pharmaceutical industry in 1995 as a sales representative for Astra, later AstraZeneca. During a 25-year span at AstraZeneca, Jens held numerous roles in Commercial & Investor Relations, spanning local & global responsibilities as well as development of phase 2/3 programs to maximise the commercial value for o

      10/25/21 2:45:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences Announces Leadership Appointments and Formation of IGM Infectious Diseases and IGM Autoimmunity and Inflammation Business Units

      – John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious Diseases – – Mary Beth Harler, M.D., Appointed as President of IGM Autoimmunity and Inflammation – MOUNTAIN VIEW, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the formation of two business units: IGM Infectious Diseases and IGM Autoimmunity and Inflammation. These new business units will utilize and build upon IGM's platform technology to create and develop novel IgM and IgA antibodies to ad

      10/11/21 4:05:00 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Medivir appoints Malene Jensen as VP Clinical Development

      STOCKHOLM, July 1, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Malene Jensen as Vice President Clinical Development. She will assume her role as VP Clinical Development after the summer, at the latest October 1, 2021. Malene Jensen will also join the company's executive team. Malene Jensen has held various leadership positions within Clinical Development in the pharmaceutical industry for the past 15 years, including at AstraZeneca, Affibody and most recently as Director Global Clinical Development at Sedana Medical. She holds a PhD in Clinical Neuroscience from Karolinska Institutet in Stockholm. "We are pleased to welcome Malene and her vast cl

      7/1/21 11:54:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by IGM Biosciences Inc.

      SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)

      11/14/24 1:22:39 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IGM Biosciences Inc.

      SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)

      11/12/24 10:32:10 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IGM Biosciences Inc.

      SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)

      8/2/24 6:41:27 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care